Lineage Cell Therapeutics, Inc. Announces Executive Changes, Effective June 21, 2021
June 16, 2021 at 07:15 am EDT
Share
On June 16, 2021, Lineage Cell Therapeutics, Inc. (announced that Kevin L. Cook will be appointed Chief Financial Officer, effective June 21, 2021. In this capacity, Mr. Cook will serve as the Company's principal financial and accounting officer. Mr. Cook, 50, previously served as Chief Operating Officer of Grade Water and Power, LLC, an investment firm, a position he held from March 2020 to June 2021. In connection with Mr. Cook's appointment as Chief Financial Officer, effective June 21, 2021, Alexandra Hernandez, Lineage's Sr. Director of Finance and Controller, will cease serving as Lineage's interim principal accounting officer.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
LINEAGE CELL THERAPEUTICS, INC. 
